The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin
Open accessAbstract
OBJECTIVE—Numerous studies have identified an increased risk of cancer in type 2 diabetes. We explored the association between antidiabetic therapies and cancer-related mortality in patients with type 2 diabetes, postulating that agents that increase insulin levels might promote cancer. RESEARCH DESIGN AND METHODS—This was a population-based cohort study using administrative databases from Saskatchewan Health. Cancer-related mortality was compared among inception cohorts of metformin users and sulfonylurea monotherapy users. Multivariate Cox regression was used to estimate the hazard ratio (HR) of cancer-related mortality, after adjusting for age, sex, insulin use, and chronic disease score. All statistical tests were two-sided. RESULTS—We identified 10,309 new users of metformin or sulfonylureas with an average follow-up of 5.4 ± 1.9 years (means ± SD). The mean age for the cohort was 63.4 ± 13.3 years, and 55% were men. Cancer mortality over follow-up was 4.9% (162 of 3,340) for sulfonylurea monotherapy users, 3.5% (245 of 6,969) for metformin users, and 5.8% (84 of 1,443) for subjects who used insulin. After multivariate adjustment, the sulfonylurea cohort had greater cancer-related mortality compared with the metformin cohort (adjusted HR 1.3 [95% CI 1.1–1.6]; P = 0.012). Insulin use was associated with an adjusted HR of cancer-related mortality of 1.9 (95% CI 1.5–2.4; P < 0.0001). CONCLUSIONS—Patients with type 2 diabetes exposed to sulfonylureas and exogenous insulin had a significantly increased risk of cancer-related mortality compared with patients exposed to metformin. It is uncertain whether this increased risk is related to a deleterious effect of sulfonylurea and insulin or a protective effect of metformin or due to some unmeasured effect related to both choice of therapy and cancer risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The reduced risk of cancer and cancer mortality observed in these studies has been consistently in the range of 25% to 30% [135-139,145-147].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [147]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Results of a growing number of observational human studies suggest that treatment with metformin (relative to other glucose-lowering therapies) is associated with reduced risk of cancer (89–93) or cancer mortality (94).”
From Diabetes and Cancer (2010) · cites this paper as [90]
In the citing paper
“Patients with type 2 diabetes who are prescribed metformin had a lower risk of cancer compared to patients who did not take it.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [147]
In the citing paper
“Patients with type 2 diabetes exposed to sulfonylureas and exogenous insulin had a significantly increased risk of cancer-related mortality compared with patients exposed to metformin.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [147]
In the citing paper
“A small number of observational studies found a higher risk of cancer or cancer death among individuals with diabetes treated with sulfonylureas compared with those treated with metformin or other diabetes medications (90–92,110).”
From Diabetes and Cancer (2010) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Hawley, S. A., Boudeau, J., Reid, J. L., Mustard, K. J., Udd, L., Mäkelä, T. P., Alessi, D. R., & Hardie, D. G. (2003) · Journal of Biology · doi:10.1186/1475-4924-2-28 · Cited by 1,694
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
A chronic disease score from automated pharmacy data
Korff, M. V., Wagner, E. H., & Saunders, K. W. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90016-g · Cited by 962
Giovannucci, E. L. (1995) · Cancer Causes & Control · doi:10.1007/bf00052777 · Cited by 808
Diabetes Mellitus as a Predictor of Cancer Mortality in a Large Cohort of US Adults
Coughlin, S. S., Calle, E. E., Teras, L. R., Petrelli, J. M., & Thun, M. J. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh161 · Cited by 795
Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis
Everhart, J. (1995) · JAMA · doi:10.1001/jama.273.20.1605 · Cited by 747
Johnson, J. A., Majumdar, S. R., Simpson, S. H., & Toth, E. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2244 · Cited by 421
Self-citationProspective Study of Adult Onset Diabetes Mellitus (Type 2) and Risk of Colorectal Cancer in Women
Hu, F. B., Manson, J. E., Liu, S., Hunter, D. J., Colditz, G. A., Michels, K. B., Speizer, F. E., & Giovannucci, E. L. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.6.542 · Cited by 420
Cited by
Sorted by citations
Items 101–200 of 933
Tsilidis, K. K., Capothanassi, D., Allen, N. E., Rizos, E. C., López, D. S., van Veldhoven, K., Sacerdote, C., Ashby, D., Vineis, P., Tzoulaki, I., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0584 · Cited by 192
Screening of colorectal cancer: present and future
Maida, M. F., Macaluso, F. S., Ianiro, G., Mangiola, F., Sinagra, E., Hold, G. L., Maida, C. D., Cammarota, G., Gasbarrini, A., & Scarpulla, G. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1392243 · Cited by 192
Pothiwala, P., Jain, S. K., & Yaturu, S. (2009) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2008.0065 · Cited by 192
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Pοlyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. Α., Katsiki, N., UNDERWOOD, P. C., Park, K., Seufert, J., Kang, E. S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 196
The Role of Metformin in the Management of NAFLD
Mazza, A., Fruci, B., Garinis, G. A., Giuliano, S., Malaguarnera, R., & Belfiore, A. (2011) · Experimental Diabetes Research · doi:10.1155/2012/716404 · Cited by 189
Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth
Algire, C., Zakikhani, M., Blouin, M.-J., Shuai, J. H., & Pollak, M. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0038 · Cited by 185
Bi, Y., Lu, J., Wang, W., Mu, Y., Zhao, J., Liu, C., Chen, L., Shi, L., Li, Q., Wan, Q., et al. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12108 · Cited by 187
Fatty Acid Synthase: Association with Insulin Resistance, Type 2 Diabetes, and Cancer
Menéndez, J. A., Vázquez‐Martín, A., Ortega, F. J., & Fernández‐Real, J. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.115352 · Cited by 182
Metabolic alterations and targeted therapies in prostate cancer
Flavin, R., Zadra, G., & Loda, M. F. (2010) · The Journal of Pathology · doi:10.1002/path.2809 · Cited by 178
Revisiting the hallmarks of cancer: The role of hyaluronan
Caon, I., Bartolini, B., Parnigoni, A., Caravà, E., Moretto, P., Viola, M., Karousou, E. G., Vigetti, D., & Passi, A. G. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.007 · Cited by 181
Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Uchiyama, T., Suzuki, K., Nozaki, Y., Yoneda, K., Fujita, K., Yoneda, M., et al. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20637 · Cited by 181
Goodwin, P. J., Stambolic, V., Lemieux, J., Chen, B. E., Parulekar, W. R., Gelmon, K. A., Hershman, D. L., Hobday, T. J., Ligibel, J. A., Mayer, I. A., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1224-1 · Cited by 178
Home, P. D., Kahn, S. E., Jones, N. P., Noronha, D., Beck‐Nielsen, H., & Viberti, G. C. (2010) · Diabetologia · doi:10.1007/s00125-010-1804-y · Cited by 176
Metformin selectively affects human glioblastoma tumor-initiating cell viability
Würth, R., Pattarozzi, A., Gatti, M., Bajetto, A., Corsaro, A., Parodi, A., Sirito, R., Massollo, M., Marini, C., Zona, G., et al. (2012) · Cell Cycle · doi:10.4161/cc.23050 · Cited by 176
Obesity related hyperinsulinaemia and hyperglycaemia and cancer development
Becker, S., Dossus, L., & Kaaks, R. (2009) · Archives of Physiology and Biochemistry · doi:10.1080/13813450902878054 · Cited by 176
Hardie, D. G. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390001 · Cited by 180
Bowker, S. L., Majumdar, S. R., Veugelers, P. J., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/dc06-0997 · Cited by 175
Self-citationPhoenix, K. N., Vumbaca, F., & Claffey, K. P. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9916-5 · Cited by 173
Anisimov, V. N., Egormin, P. A., Piskunova, T. S., Popovich, I. G., Tyndyk, M. L., Yurova, M. N., Zabezhinski, M. A., Anikin, I. V., Karkach, A. S., & Romanyukha, A. A. (2010) · Cell Cycle · doi:10.4161/cc.9.1.10407 · Cited by 146
Histological evaluation of AMPK signalling in primary breast cancer
Hadad, S. M., Baker, L., Quinlan, P., Robertson, K. E., Bray, S. E., Thomson, G., Kellock, D., Jordan, L. B., Purdie, C. A., Hardie, D. G., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-307 · Cited by 177
Caloric restriction: From soup to nuts
Spindler, S. R. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2009.10.003 · Cited by 169
Mantovani, A., & Targher, G. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.04.41 · Cited by 170
Cancer occurrence in Danish diabetic patients: duration and insulin effects
Carstensen, B., Witte, D. R., & Friis, S. (2011) · Diabetologia · doi:10.1007/s00125-011-2381-4 · Cited by 167
The Relationship Between Diabetes Mellitus and Cancers and Its Underlying Mechanisms
Zhu, B., & Qu, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.800995 · Cited by 174
Bowker, S. L., Yasui, Y., Veugelers, P. J., & Johnson, J. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1750-8 · Cited by 166
Self-citationThe Influence of Type 2 Diabetes and Glucose-Lowering Therapies on Cancer Risk in the Taiwanese
Hsieh, M.-C., Lee, T.-C., Cheng, S.-M., Tu, S., Yen, M., & Tseng, C. (2012) · Experimental Diabetes Research · doi:10.1155/2012/413782 · Cited by 166
Tan, B., Yao, W., Ge, J., Peng, X., Du, X., Zhang, R., Yao, B., Xie, K., Li, L., Dong, H., et al. (2011) · Cancer · doi:10.1002/cncr.26151 · Cited by 161
Targeting cancer metabolism – aiming at a tumour's sweet-spot
Jones, N. P., & Schulze, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.017 · Cited by 164
Metformin intake is associated with better survival in ovarian cancer
Kumar, S., Meuter, A., Thapa, P. B., Langstraat, C. L., Giri, S., CHIEN, J. R., Rattan, R., Cliby, W. A., & Shridhar, V. (2012) · Cancer · doi:10.1002/cncr.27706 · Cited by 161
Yin, M., Zhou, J., Gorak, E. J., & Quddus, F. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0111 · Cited by 157
Saito, S., Furuno, A., Sakurai, J., Sakamoto, A., Park, H.-R., Shin‐ya, K., Tsuruo, T., & Tomida, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2689 · Cited by 164
Diabetes and pancreatic cancer
Cui, Y., & Andersen, D. K. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0105 · Cited by 160
Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?
Xu, Y., Xue, D., Bankhead, A., & Neamati, N. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01013 · Cited by 173
Metformin is associated with improved survival in endometrial cancer
Ko, E. M., Walter, P. J., Jackson, A. L., Clark, L. H., Franasiak, J. M., Bolac, C. S., Havrilesky, L. J., Secord, A. A., Moore, D. T., Gehrig, P. A., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.11.021 · Cited by 159
Targeting the Metabolic Microenvironment of Tumors
Bailey, K. M., Wojtkowiak, J. W., Hashim, A. I., & Gillies, R. J. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00004-x · Cited by 157
He, X., Tu, S., Lee, M., & Yeung, S. J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr020 · Cited by 153
Rizos, C. V., & Elisaf, M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.02.038 · Cited by 155
Epidemiological aspects of neoplasms in diabetes
Nicolucci, A. (2010) · Acta Diabetologica · doi:10.1007/s00592-010-0187-3 · Cited by 154
Metformin and cancer: An existing drug for cancer prevention and therapy (Review)
Zi, F., Zi, H., Li, Y., He, J., Shi, Q., & Cai, Z. (2017) · Oncology Letters · doi:10.3892/ol.2017.7412 · Cited by 156
A new link between diabetes and cancer: enhanced WNT/β-catenin signaling by high glucose
García-Jiménez, C., García-Martínez, J. M., Chocarro-Calvo, A., & De la Vieja, A. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0152 · Cited by 151
New Perspective for an Old Antidiabetic Drug: Metformin as Anticancer Agent
Leone, A., Gennaro, E. D., Bruzzese, F., Avallone, A., & Budillon, A. (2013) · Cancer treatment and research · doi:10.1007/978-3-642-38007-5_21 · Cited by 150
Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis
Zhang, H., Gao, C., Fang, L., Zhao, H.-C., & Yao, S. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.719926 · Cited by 148
Hanna, R. K., Zhou, C., Malloy, K., Sun, L., Zhong, Y., Gehrig, P. A., & Bae-Jump, V. L. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.01.009 · Cited by 150
Mechanisms linking obesity and cancer
Louie, S. M., Roberts, L. S., & Nomura, D. K. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.02.008 · Cited by 152
Wu, L., Zhu, J., Prokop, L. J., & Murad, M. H. (2015) · Scientific Reports · doi:10.1038/srep10147 · Cited by 144
Diabetes and cancer: Pathophysiological fundamentals of a ‘dangerous affair’
Cignarelli, A., Genchi, V. A., Caruso, I., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.04.002 · Cited by 156
Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials
Johnson, J. A., & Bowker, S. L. (2010) · Diabetologia · doi:10.1007/s00125-010-1933-3 · Cited by 145
Self-citationVitale-Cross, L. A., Molinolo, A., Martín, D., Younis, R. H., Maruyama, T., Patel, V., Chen, W., Schneider, A., & Gutkind, J. S. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0502 · Cited by 145
Metabolic Roles of AMPK and Metformin in Cancer Cells
Choi, Y. K., & Park, K. (2013) · Molecules and Cells · doi:10.1007/s10059-013-0169-8 · Cited by 150
Sormendi, S., & Wielockx, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00040 · Cited by 147
Diabetes and Pancreatic Cancer: Chicken or Egg?
Magruder, J. T., Elahi, D., & Andersen, D. K. (2011) · Pancreas · doi:10.1097/mpa.0b013e318209e05d · Cited by 140
Metformin for aging and cancer prevention
Anisimov, V. N. (2010) · Aging · doi:10.18632/aging.100230 · Cited by 142
60 years of metformin use: a glance at the past and a look to the future
Marshall, S. M. (2017) · Diabetologia · doi:10.1007/s00125-017-4343-y · Cited by 139
The strange case of AMPK and cancer: Dr Jekyll or Mr Hyde?
Vara‐Ciruelos, D., Russell, F. M., & Hardie, D. G. (2019) · Open Biology · doi:10.1098/rsob.190099 · Cited by 140
Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models
Lengyel, E. R., Litchfield, L. M., Mitra, A. K., Nieman, K. M., Mukherjee, A., Zhang, Y., Johnson, A., Bradaric, M. J., Lee, W., & Romero, I. L. (2014) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2014.10.026 · Cited by 137
Metformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes
Azoulay, L., Dell’Aniello, S., Gagnon, B., Pollak, M., & Suissa, S. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0940 · Cited by 133
Is it Time to Test Metformin in Breast Cancer Clinical Trials?
Cazzaniga, M., Bonanni, B., Guerrieri‐Gonzaga, A., & DeCensi, A. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0871 · Cited by 134
Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer
Renehan, A. G., Yeh, H., Johnson, J. A., Wild, S. H., Gale, E. A. M., & Møller, H. (2012) · Diabetologia · doi:10.1007/s00125-012-2526-0 · Cited by 132
Self-citationSex and gender influences on pharmacological response: an overview
Franconi, F., & Campesi, I. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.922866 · Cited by 139
Expanding roles for AMP‐activated protein kinase in neuronal survival and autophagy
Poels, J., Spasić, M. R., Callaerts, P., & Norga, K. (2009) · BioEssays · doi:10.1002/bies.200900003 · Cited by 130
Yasmeen, A., Beauchamp, M.-C., Piura, E., Segal, E., Pollak, M., & Gotlieb, W. H. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.02.021 · Cited by 135
Habib, S. L., & Rojna, M. (2013) · ISRN Oncology · doi:10.1155/2013/583786 · Cited by 131
Gruzman, A., Babai-Shani, G., & Sasson, S. (2009) · The Review of Diabetic Studies · doi:10.1900/rds.2009.6.13 · Cited by 128
Soares, H. P., Ni, Y., Kisfalvi, K., Sinnett‐Smith, J. W., & Rozengurt, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057289 · Cited by 127
Type 2 diabetes mellitus as risk factor for colorectal cancer
Berster, J. M., & Göke, B. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450802008455 · Cited by 126
Metformin and neoplasia: Implications and indications
Aljada, A., & Mousa, S. A. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.004 · Cited by 128
Dixit, S., Maiya, A. G., & Shastry, B. A. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.12.006 · Cited by 136
Metformin: An Emerging New Therapeutic Option for Targeting Cancer Stem Cells and Metastasis
Rattan, R., Fehmi, R.-A., & Munkarah, A. R. (2012) · Journal of Oncology · doi:10.1155/2012/928127 · Cited by 126
Singh, S., Singh, P. P., Singh, A. G., Murad, M. H., McWilliams, R. R., & Chari, S. T. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.7 · Cited by 125
Truong, M., Kim, H. G., Khanal, T., Choi, J. H., Kim, D. H., Jeong, T. C., & Jeong, H. G. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.05.010 · Cited by 124
van Staa, T. P., Patel, D., Gallagher, A. M., & Bruin, M. L. D. (2011) · Diabetologia · doi:10.1007/s00125-011-2390-3 · Cited by 121
ESFAHANIAN, N., SHAKIBA, Y., NIKBIN, B., SORAYA, H., MALEKI-DIZAJI, N., GHAZI-KHANSARI, M., & GARJANI, A. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.753 · Cited by 120
Morgillo, F., Sasso, F. C., Corte, C. M. D., Vitagliano, D., D’Aiuto, E., Troiani, T., Martinelli, E., Vita, F. D., Orditura, M., Palma, R. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2777 · Cited by 121
Targeting mitochondria for cancer therapy
Hockenbery, D. M. (2010) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20552 · Cited by 124
Diabetes and Cancer: Is Diabetes Causally Related to Cancer?
Suh, S., & Kim, K. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.3.193 · Cited by 122
Dowling, R. J., Niraula, S., Chang, M. C., Done, S. J., Ennis, M., McCready, D. R., Leong, W. L., Escallon, J. M., Reedijk, M., Goodwin, P. J., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0540-0 · Cited by 117
Doses of Insulin and Its Analogues and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients
Mannucci, E., Monami, M., Balzi, D., Cresci, B., Pala, L., Melani, C., Lamanna, C., Bracali, I., Bigiarini, M., Barchielli, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0476 · Cited by 114
Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression
Ng, C.-A. W., Jiang, A. A., Toh, E. M. S., Ng, C. H., Ong, Z. H., Peng, S., Tham, H. Y., Sundar, R., Chong, C. S., & Khoo, C. M. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03676-x · Cited by 114
The effect of metformin and thiazolidinedione use on lung cancer in diabetics
Mazzone, P. J., Rai, H., Beukemann, M., Meng, X., Jain, A., & Sasidhar, M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-410 · Cited by 112
Targeting Cancer Metabolism - Revisiting the Warburg Effects
Tran, Q., Lee, H., Park, J., Kim, S., & Park, J. (2016) · Toxicological Research · doi:10.5487/tr.2016.32.3.177 · Cited by 116
Obesity, Inflammation, and Postmenopausal Breast Cancer: Therapeutic Implications
Macciò, A., & Madeddu, C. (2011) · The Scientific World JOURNAL · doi:10.1100/2011/806787 · Cited by 111
Impact of Diabetes and Hyperglycemia on Survival in Advanced Breast Cancer Patients
Villarreal-Garza, C. M., Shaw-Dulin, R. J., Lara-Medina, F. U., Bacon, L., Rivera, D., Urzua, L., Águila, C., Ramírez-Morales, R., Santamaria, J., Bargalló, E., et al. (2012) · Experimental Diabetes Research · doi:10.1155/2012/732027 · Cited by 111
Janjetović, K., Vucicevic, L. M., Misirkic-Marjanovic, M., Vilimanovich, U., Tovilović-Kovačević, G., Zogovic, N. S., Nikolić, Z., Jovanović, S., Bumbasirevic, V. Z., Trajković, V., et al. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.11.005 · Cited by 115
Perseghin, G., Calori, G., Lattuada, G., Ragogna, F., Dugnani, E., Garancini, M. P., Crosignani, P., Villa, M., Bosi, E., Ruotolo, G., et al. (2012) · Acta Diabetologica · doi:10.1007/s00592-011-0361-2 · Cited by 110
The LKB1 tumor suppressor kinase in human disease
Katajisto, P., Vallenius, T., Vaahtomeri, K., Ekman, N., Udd, L., Tiainen, M., & Mäkelä, T. P. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.003 · Cited by 113
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer‐related mortality
Monami, M., Balzi, D., Lamanna, C., Barchielli, A., Masotti, G., Buiatti, E., Marchionni, N., & Mannucci, E. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.736 · Cited by 111
Zhuang, Y., & Miskimins, W. K. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0343 · Cited by 113
Metformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients
Monami, M., Colombi, C., Balzi, D., Dicembrini, I., Giannini, S., Melani, C., Vitale, V., Romano, D., Barchielli, A., Marchionni, N., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1287 · Cited by 110
Anisimov, V. N. (2007) · Cancer Control · doi:10.1177/107327480701400104 · Cited by 114
for the DIGAMI 2 Investigators, Mellbin, L., Malmberg, K., Norhammar, A., Wedel, H., & Rydén, L. (2011) · Diabetologia · doi:10.1007/s00125-011-2084-x · Cited by 107
Chen, T., Lin, C., Huang, P., & Wen, C. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06664.x · Cited by 107
Nishida, M., Yamashita, N., Ogawa, T., Koseki, K., Warabi, E., Ohue, T., Komatsu, M., Matsushita, H., Kakimi, K., Kawakami, E., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002954 · Cited by 109
Ranc, K., Jørgensen, M. E., Friis, S., & Carstensen, B. (2014) · Diabetologia · doi:10.1007/s00125-014-3186-z · Cited by 106
In vitro and in vivo anti-melanoma action of metformin
Janjetović, K., Harhaji-Trajkovic, L. M., Misirkic-Marjanovic, M., Vucicevic, L. M., Stevanović, D., Zogovic, N. S., Šumarac-Dumanović, M., Micić, D., & Trajković, V. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.07.004 · Cited by 110
Obesity, metabolism and the microenvironment: Links to cancer
Makowski, L., Sundaram, S., & Johnson, A. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.119606 · Cited by 106
Breast cancer: Current and future endocrine therapies
Palmieri, C., Patten, D. K., Januszewski, A. P., Zucchini, G., & Howell, S. J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.08.001 · Cited by 102
Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome
Lohmann, A. E., Goodwin, P. J., Chlebowski, R. T., Pan, K., Stambolic, V., & Dowling, R. J. O. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.6187 · Cited by 101
Liu, H., Scholz, C. W., Zang, C., Schefe, J. H., Habbel, P., Regierer, A. C., Schulz, C., Possinger, K., & Eucker, J. (2012) · PubMed · Cited by 98
Insulin, insulin-like growth factors and neoplasia
Pollak, M. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.08.004 · Cited by 100
Metformin and Prostate Cancer: a New Role for an Old Drug
Whitburn, J., Edwards, C. M., & Sooriakumaran, P. (2017) · Current Urology Reports · doi:10.1007/s11934-017-0693-8 · Cited by 98
Metadata
- Authors
- Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A.
- Affiliations
- University of Alberta (CA)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-02-01
- Volume
- 29
- Issue
- 2
- Pages
- 254-258
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2156370651
- Cited by
- 933
- References
- 37
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 28 · 2023: 32 · 2022: 26 · 2021: 25 · 2020: 33 · 2019: 37 · 2018: 33 · 2017: 45 · 2016: 43 · 2015: 52 · 2014: 55 · 2013: 96 · 2012: 93
- FWCI
- 16.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cancer mortality, sulfonylureas, insulin therapy, metformin, antidiabetic drugs, cancer risk
- MeSH terms
- Aged, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Insulin, Male, Metformin, Middle Aged, Neoplasms, Retrospective Studies, Risk Factors, Saskatchewan, Severity of Illness Index, Sulfonylurea Compounds, Cohort Studies, Comorbidity, Multivariate Analysis, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
